Literature DB >> 28405881

Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review.

Roland Därr1, Matthias Kuhn2, Christoph Bode3, Stefan R Bornstein4, Karel Pacak5, Jacques W M Lenders4,6, Graeme Eisenhofer4,7.   

Abstract

PURPOSE: To determine the accuracy of biochemical tests for the diagnosis of pheochromocytoma and paraganglioma.
METHODS: A search of the PubMed database was conducted for English-language articles published between October 1958 and December 2016 on the biochemical diagnosis of pheochromocytoma and paraganglioma using immunoassay methods or high-performance liquid chromatography with coulometric/electrochemical or tandem mass spectrometric detection for measurement of fractionated metanephrines in 24-h urine collections or plasma-free metanephrines obtained under seated or supine blood sampling conditions.
RESULTS: Application of the Standards for Reporting of Diagnostic Studies Accuracy Group criteria yielded 23 suitable articles. Summary receiver operating characteristic analysis revealed sensitivities/specificities of 94/93% and 91/93% for measurement of plasma-free metanephrines and urinary fractionated metanephrines using high-performance liquid chromatography or immunoassay methods, respectively. Partial areas under the curve were 0.947 vs. 0.911. Irrespective of the analytical method, sensitivity was significantly higher for supine compared with seated sampling, 95 vs. 89% (p < 0.02), while specificity was significantly higher for supine sampling compared with 24-h urine, 95 vs. 90% (p < 0.03). Partial areas under the curve were 0.942, 0.913, and 0.932 for supine sampling, seated sampling, and urine. Test accuracy increased linearly from 90 to 93% for 24-h urine at prevalence rates of 0.0-1.0, decreased linearly from 94 to 89% for seated sampling and was constant at 95% for supine conditions.
CONCLUSIONS: Current tests for the biochemical diagnosis of pheochromocytoma and paraganglioma show excellent diagnostic accuracy. Supine sampling conditions and measurement of plasma-free metanephrines using high-performance liquid chromatography with coulometric/electrochemical or tandem mass spectrometric detection provides the highest accuracy at all prevalence rates.

Entities:  

Keywords:  Diagnostic accuracy; High-performance liquid chromatography; Immunoassay; Metanephrines; Paraganglioma; Pheochromocytoma

Mesh:

Substances:

Year:  2017        PMID: 28405881      PMCID: PMC6297899          DOI: 10.1007/s12020-017-1300-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  54 in total

1.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; David Moher; Drummond Rennie; Henrica C W de Vet; Jeroen G Lijmer
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

2.  Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital.

Authors:  M Ariton; C S Juan; T W AvRuskin
Journal:  Endocr Pract       Date:  2000 May-Jun       Impact factor: 3.443

3.  Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass.

Authors:  N Unger; J Hinrichs; T Deutschbein; H Schmidt; M K Walz; K Mann; S Petersenn
Journal:  Exp Clin Endocrinol Diabetes       Date:  2012-06-13       Impact factor: 2.949

4.  Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan.

Authors:  Masao Omura; Jun Saito; Kunio Yamaguchi; Yukio Kakuta; Tetsuo Nishikawa
Journal:  Hypertens Res       Date:  2004-03       Impact factor: 3.872

5.  A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines.

Authors:  Anna M Sawka; Roman Jaeschke; Ravinder J Singh; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

6.  Comparison of free plasma metanephrines enzyme immunoassay with (131)I-MIBG scan in diagnosis of pheochromocytoma.

Authors:  Yun-Chao Gao; Han-Kui Lu; Quan-Yong Luo; Li-Bo Chen; Ying Ding; Rui-Sen Zhu
Journal:  Clin Exp Med       Date:  2008-07-11       Impact factor: 3.984

7.  Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients.

Authors:  Jan Václavík; David Stejskal; Borek Lacnák; Marie Lazárová; Libor Jedelský; Lenka Kadalová; Marie Janosová; Zdenek Frysák; Petr Vlcek
Journal:  J Hypertens       Date:  2007-07       Impact factor: 4.844

8.  Determination of metanephrines in plasma by liquid chromatography with electrochemical detection.

Authors:  J W Lenders; G Eisenhofer; I Armando; H R Keiser; D S Goldstein; I J Kopin
Journal:  Clin Chem       Date:  1993-01       Impact factor: 8.327

9.  Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma.

Authors:  Peter E Hickman; Michelle Leong; Julia Chang; Susan R Wilson; Brett McWhinney
Journal:  Pathology       Date:  2009-02       Impact factor: 5.306

Review 10.  The protean manifestations of pheochromocytoma.

Authors:  W M Manger
Journal:  Horm Metab Res       Date:  2009-02-25       Impact factor: 2.936

View more
  25 in total

1.  No effect of acidification or freezing on urinary metanephrine levels.

Authors:  L C Pinto; C K Kramer; J L Camargo; L H Canani; J L Gross; C B Leitão
Journal:  J Endocrinol Invest       Date:  2019-06-21       Impact factor: 4.256

Review 2.  Comprehensive review of evaluation and management of cardiac paragangliomas.

Authors:  Sri Harsha Tella; Abhishek Jha; David Taïeb; Keith A Horvath; Karel Pacak
Journal:  Heart       Date:  2020-05-22       Impact factor: 5.994

Review 3.  MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives.

Authors:  Vincent Amodru; David Taieb; Carole Guerin; Pauline Romanet; Nunzia Paladino; Thierry Brue; Thomas Cuny; Anne Barlier; Frederic Sebag; Frederic Castinetti
Journal:  Endocrine       Date:  2020-05-10       Impact factor: 3.633

Review 4.  Pheochromocytomas and Hypertension.

Authors:  Joseph M Pappachan; Nyo Nyo Tun; Ganesan Arunagirinathan; Ravinder Sodi; Fahmy W F Hanna
Journal:  Curr Hypertens Rep       Date:  2018-01-22       Impact factor: 5.369

5.  Quantitative analysis of 68Ga-DOTA(0)-Tyr(3)-octreotate positron emission tomography/computed tomography imaging for the differential diagnosis of primary pheochromocytoma and paraganglioma.

Authors:  Guangyu Ma; Jin Du; Xiaojun Zhang; Jiajin Liu; Xiaodan Xu; Baixuan Xu; Zhiwei Guan
Journal:  Quant Imaging Med Surg       Date:  2022-04

Review 6.  Surgical approach to patients with pheochromocytoma.

Authors:  Dhaval Patel
Journal:  Gland Surg       Date:  2020-02

7.  A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position.

Authors:  Jessica Boyd; Alexander A Leung; Hossein Sm Sadrzadeh; Christina Pamporaki; Karel Pacak; Timo Deutschbein; Stephanie Fliedner; Gregory A Kline
Journal:  Eur J Endocrinol       Date:  2019-09       Impact factor: 6.664

Review 8.  Adrenal Incidentaloma.

Authors:  Mark Sherlock; Andrew Scarsbrook; Afroze Abbas; Sheila Fraser; Padiporn Limumpornpetch; Rosemary Dineen; Paul M Stewart
Journal:  Endocr Rev       Date:  2020-12-01       Impact factor: 19.871

9.  A First Case Report of Orbital Extra-Adrenal Paraganglioma in Cat.

Authors:  Leonardo Leonardi; Raluca Ioana Rizac; Ilaria Pettinari; Luca Mechelli; Carlo De Feo
Journal:  Vet Sci       Date:  2021-05-14

Review 10.  Approach to the Patient With Adrenal Incidentaloma.

Authors:  Irina Bancos; Alessandro Prete
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.